GlaxoSmithKline Plc (GSK)

40.70
0.63 1.57
NYSE : Health Technology
Prev Close 40.07
Open 40.17
Day Low/High 40.05 / 40.76
52 Wk Low/High 31.43 / 48.25
Volume 3.78M
Avg Volume 3.18M
Exchange NYSE
Shares Outstanding 2.51B
Market Cap 102.02B
EPS 2.40
P/E Ratio 22.94
Div & Yield 1.97 (4.86%)

Latest News

SPACs Aren't Just for Trading: 2 Attractive Buy and Hold Opportunities

SPACs Aren't Just for Trading: 2 Attractive Buy and Hold Opportunities

I like putting some of my money with incredibly successful folks who are well-connected and have a history of success.

China Headline Risk, Valuation Station and a Workday Play

China Headline Risk, Valuation Station and a Workday Play

WDAY looks ready to break out as traders weigh wether markets are now overbought after this 2-day run.

Jim Cramer: We Have a Rip Snorting Rally Unfathomable 2 Months Ago

Jim Cramer: We Have a Rip Snorting Rally Unfathomable 2 Months Ago

So what's the narrative? Simple: the recession is ending, it turned out to be a V recession and recovery after all.

Sell Signals, 'Operation Warp Speed,' Trading Notes

Sell Signals, 'Operation Warp Speed,' Trading Notes

Trump administration taps former GlaxoSmithKline exec as head of vaccine task force, and how I'm playing Walmart and Datadog.

Jim Cramer: Let the Froth Wash Out

Jim Cramer: Let the Froth Wash Out

Let's look at the stocks that will get crushed and that you can't touch right now.

Jim Cramer: Reopening Is Necessary, but Based on Little More Than Hope

Jim Cramer: Reopening Is Necessary, but Based on Little More Than Hope

It's imperative that people get back to work, so we have this great compromise -- let's see how it might play out.

GlaxoSmithKline Charts Prescribe Positive Outlook as It Chases Covid-19 Vaccine

GlaxoSmithKline Charts Prescribe Positive Outlook as It Chases Covid-19 Vaccine

The drugmaker that is partnering with Sanofi to develop a vaccine has seen its shares push higher after declining to a low in late March.

Jim Cramer: Don't Mistake the Rally for Cheering

Jim Cramer: Don't Mistake the Rally for Cheering

There is no joy in stockville -- instead we have big companies with stocks rising. Here's why that is and what you need to understand about the rally amid the crisis.

Taking Stock of Recent Dividend Hikes

Taking Stock of Recent Dividend Hikes

We've seen some high quarterly dividend increases of late, so let's pick out the crème of the crop.

GlaxoSmithKline: The Charts Are Pointing Higher

GlaxoSmithKline: The Charts Are Pointing Higher

Our latest analysis and trading strategy for the the big pharma stock.

5 Best Buys for 2020 from Argus Research

5 Best Buys for 2020 from Argus Research

Analysts from the independent research firm review their picks from last year and share their new favorites.

GlaxoSmithKline Could Trade Up to the $75 Area in the Months Ahead

GlaxoSmithKline Could Trade Up to the $75 Area in the Months Ahead

Let's see what we might expect.

GlaxoSmithKline Could Rise 20% From Here

GlaxoSmithKline Could Rise 20% From Here

Shares of the pharma company have broken out on our Point and Figure chart.

Jim Cramer: Drug Stocks Are Too Cheap

Jim Cramer: Drug Stocks Are Too Cheap

These stocks are priced for total imperfection. That's just what you want.

GlaxoSmithKline Could Be Close to a Major Upside Move

GlaxoSmithKline Could Be Close to a Major Upside Move

The long-term technical view of GSK is very bullish.

China's Drugmakers Under Scrutiny After Stanford Admissions Scandal

China's Drugmakers Under Scrutiny After Stanford Admissions Scandal

Chinese authorities are auditing the books of 77 drugmakers, including three multinationals, they say were selected at random. Were they motivated by embarrassment over a college-admissions payment made by a Chinese pharmaceuticals' tycoon?

Jim Cramer: How to Win Now, With or Without China

Jim Cramer: How to Win Now, With or Without China

If we can advance without China then who the heck knows where we can go with it.

Jim Cramer: 7 Trends That Can Guide Us Through This Turmoil

Jim Cramer: 7 Trends That Can Guide Us Through This Turmoil

These themes are working despite the turmoil in Washington and slowing global growth.

Jim Cramer: This Market Takes Its Cue From the Positive and Ignores the Negative

Jim Cramer: This Market Takes Its Cue From the Positive and Ignores the Negative

So far 2019 is proving to be a year where things have a habit of working out right.

Takeda Pharmaceutical CEO Talks Big Pharma Trends

Takeda Pharmaceutical CEO Talks Big Pharma Trends

One of pharma's biggest CEO's talks M&A action on the exchange.

Get Ready to Buy the Big Upside Breakout on GlaxoSmithKline

Get Ready to Buy the Big Upside Breakout on GlaxoSmithKline

Let's check out the charts.

Jim Cramer: Innovation Is on Display at the J.P. Morgan Healthcare Conference

Jim Cramer: Innovation Is on Display at the J.P. Morgan Healthcare Conference

We're out in San Francisco this week covering the amazing innovations that so many companies reveal at this annual conference.

Celgene Deal Gets the M&A Ball Rolling in the New Year

Celgene Deal Gets the M&A Ball Rolling in the New Year

It seemed just a matter of time before M&A returned to the biotech industry with a vengeance.

This 2019 Market Optimism Is Misplaced: Market Recon

This 2019 Market Optimism Is Misplaced: Market Recon

Take upbeat outlooks for equities with a grain of salt, and try these sectors to stay safe.

Pfizer Shares Jump on Monday After Company Signals Higher Price Push

Pfizer Shares Jump on Monday After Company Signals Higher Price Push

Pfizer pushes higher on price increases.

Tech Selloff Could Work in Favor of Pharmaceutical Stocks

Tech Selloff Could Work in Favor of Pharmaceutical Stocks

Pharma could be the best parking spot for your money if the market keeps trending downward.

Pfizer's Oncology Offerings Present Opportunity for Long-Term Stock Growth

Pfizer's Oncology Offerings Present Opportunity for Long-Term Stock Growth

The cancer drug market is expected to grow from a surveyed total value of $78 billion in 2015 to over $110 billion by 2020.

Novice Trade: EWU United Kingdom ETF

Novice Trade: EWU United Kingdom ETF

This at-the-money, long put shooter is a high risk trade, so use discretionary capital.